PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26322F0032Emergency ponatinib 45 MG tablets - FARGO — Millennium Pharmaceuticals, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Sep 30, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Network Contract Office 23 (36C263)

Awarding office

Millennium Pharmaceuticals, Inc

Recipient

Sep 30, 2022

PoP end

$147K

Obligated

$147K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Millennium Pharmaceuticals, Inc — $90

Contract facts

Federal

Contract number36C26322F0032

Also listed as36C263-22-F-0032

Also listed as36F79718D0586-36C26322F0032

AgencyNetwork Contract Office 23 (36C263)

Awarding officeNetwork Contract Office 23 (36C263)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentMillennium Pharmaceuticals, Inc

CAGE3FLV7

UEIENNFDLWFC6L1

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79718D0586

Place of performanceCAMBRIDGE MA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startFeb 24, 2022

PoP end (current)Sep 30, 2022

Obligated$147K

Current value$147K

Potential value$147K

EMERGENCY PONATINIB 45 MG TABLETS - FARGO is a federal award for Network Contract Office 23 (36C263) held by Millennium Pharmaceuticals, Inc. Estimated value $147K ($147K obligated). Current period of performance ends Sep 30, 2022. Last award drew 1 bidder. Place of performance: CAMBRIDGE MA.

EMERGENCY PONATINIB 45 MG TABLETS - FARGO

Recompete timing

Public

● Past PoP end (1421 days ago)

Current PoP ended Sep 30, 2022 (1421 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26322F0032?

36C26322F0032 (Emergency ponatinib 45 MG tablets - FARGO) is a Network Contract Office 23 (36C263) award with a potential value of $147K, currently held by Millennium Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C263-22-F-0032?

36C263-22-F-0032 is the dashed form of PIID 36C26322F0032 (Emergency ponatinib 45 MG tablets - FARGO), held by Millennium Pharmaceuticals, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26322F0032?

Network Contract Office 23 (36C263) awarded 36C26322F0032 to Millennium Pharmaceuticals, Inc (potential $147K).

Who is the incumbent on 36C26322F0032?

Millennium Pharmaceuticals, Inc is the incumbent. The current period of performance ends Sep 30, 2022.

When does Millennium Pharmaceuticals, Inc’s 36C26322F0032 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 15, 2022 · refreshed monthly